Celldex is developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.
Driven by our deep and longstanding experience developing antibody-based immunotherapies, Celldex’s proprietary antibody programs and technologies are supported by robust in-house capabilities, enabling the optimized discovery and development of innovative scientific programs.
Events & Presentations
View our upcoming events and recent presentations
For information on Celldex’s ongoing clinical studies, including information about how to enroll, please click here:
Celldex is always looking for passionate and talented individuals to join our team